Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Neoadjuvant Therapy × Thoracic × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 28 Lung Neoplasms 20 Adenocarcinoma of Lung 5 Adenocarcinoma, Bronchiolo-Alveolar 4 Mesothelioma, Malignant 3 Solitary Fibrous Tumor, Pleural 2 Small Cell Lung Carcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm Metastasis 1 Neoadjuvant Therapy 1 NSCLC 1 Carcinoma, Squamous Cell 1

Interventions

osimertinib 11 Pemetrexed 10 Carboplatin 10 aflutinib 8 Gefitinib 7 Drug Therapy 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡